On 13 and 18 October 2017 the CMA announced that it had launched four separate antitrust investigations into alleged anti-competitive practices regarding generic products in the pharmaceutical industry. The four investigations cover alleged anti-competitive agreements, concerted practices and, in some cases, abuse of dominance. These new investigations demonstrate that the CMA continues to be unafraid to take a robust approach to investigating anti-competitive conduct relating to generic drugs.
Also in this newsletter
European Commission raids German car manufacturers
General Court rules that watchmakers may restrict supply of parts to authorised repairers only
Hong Kong Competition Tribunal issues judgment on the right against self-incrimination
